Moreover, BTX-1188, a myc inhibitor and specific degrader of GSPT1 and IKZF1/3, is currently under investigation in a phase 1 dose-escalation trial (NCT05144334) enrolling patients with advanced solid tumors, non-Hodgkin-lymphomas and AML [60], however without specified molecular stratification regarding IKZF1 mutation status. This evidence concerns the gene IKZF1 and acute myeloid leukemia.